US judge rules against AstraZeneca in Medicare price talks challenge
2024-03-01
A federal judge in the US has upheld a law mandating certain drugmakers to engage in price negotiations with Medicare, dismissing a legal challenge brought by AstraZeneca.
"We are disappointed with the court's decision and the potential negative impact it will have on patients' access to future life-saving medicines," a spokesperson for AstraZeneca told FirstWord. "We believe our challenge is necessary to support and improve patients’ access to future life-saving medicines, and our rights as a company. There is a lot at stake here, and we are actively evaluating our path forward."
Judge Colm Connolly of US District Court in Delaware made his decision just as the UK drugmaker was set to respond to the US government's initial bid for the price of its diabetes treatment Farxiga, one of the first batch of drugs that are up for price negotiations with Medicare.
As part of the Biden administration's Inflation Reduction Act (IRA), the negotiation programme empowers Medicare to engage in direct price discussions with companies for specific high-cost medications. Ten medicines are subject to the first round of Medicare price talks, with the Centers for Medicare and Medicaid Services recently sending initial offers to the companies involved.
More to follow.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。